Medical device company Catalyst OrthoScience has introduced the patent pending 3-Peg Glenoid implant to its Catalyst CSR Total Shoulder System.
The new implant was unveiled at the American Shoulder and Elbow Surgeons (ASES) 2018 Annual Meeting in Chicago, Illinois.
Loosening of the glenoid component is the most common mode of failure in total shoulder arthroplasty. An inability to achieve long-lasting, secure fixation within the glenoid bone that can withstand the effects of repeated eccentric loading and glenohumeral translation leads to failure.
In order to address this, Catalyst has used a science-based approach to design the 3-Peg Glenoid implant with the specific goal of resolving these challenges. Key features include:
Immediate interference fit fixation in the strongest regions of the glenoid vault using a new backside anchoring element design.
Tapered walls on the bearing surface to reduce the effects of eccentric loading, which can contribute to implant loosening.
Quick, accurate placement of the implant using a streamlined procedure resulting in potential time and cost savings.
Catalyst executive chairman and CEO Brian Hutchison said: “The 3-Peg Glenoid is a great addition to our Catalyst CSR system, and it gives surgeons the option between the existing glenoid with two pegs or the new 3-Peg option.
“We have had a number of surgeons use the 3-Peg Glenoid with great results so far.”
Designed by surgeons for surgeons, the Catalyst CSR system represents the next evolution in shoulder surgery. The system includes a multi-planar stemless design which preserves bone and an elliptical humeral component that mimics the natural shoulder anatomy.
Additionally, the surgical technique and instrumentation were designed to simplify the glenoid exposure and consistently deliver a precise and accurate shoulder reconstruction.